
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is viewed favorably because its 3Q26 results beat expectations with $480.1M in revenue, 21.8% year-over-year growth, and strong proprietary product sales of $417.3M, while cash and investments of $787.6M support continued R&D. The core commercial base, including Lumryz, Vivitrol, Aristada, and Lybalvi, is generating durable cash flow and helping fund a growing neuroscience pipeline without sacrificing profitability, as management kept FY26 revenue guidance at $1.73B–$1.84B. Upbeat sentiment also reflects the orexin program, where encouraging alixorexton data in NT1, NT2, and idiopathic hypersomnia, plus upcoming readouts in year-end or early-’27 and 2027, could expand the franchise toward multi-billion-dollar revenue potential.
Bears say
Alkermes is facing a negative outlook because its earnings base is vulnerable to erosion in both royalty income and proprietary products, which could pressure profitability through the remainder of the decade. The injectable business also appears exposed to commercial headwinds and rapid competitive erosion, while significant Medicaid exposure adds reimbursement risk under the current administration. Meanwhile, the orexin program remains early stage and still needs larger-study validation of efficacy and safety, leaving the pipeline, FDA approval prospects, and the company’s heavy R&D and SG&A burden as meaningful fundamental risks.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Alkermes (ALKS) Forecast
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares